Molecular Characterization of Advanced Non-small Cell Lung Cancer Patients by CfDNA Analysis: Experience from Routine Laboratory Practice

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2021 Apr 12

PMID 33841957

Citations 3

Authors

Jose Manuel Gonzalez de Aledo-Castillo

Ainara Arcocha

Ivan Victoria

Ana Isabel Martinez-Puchol

Cristina Sanchez

Pedro Jares

Gabriel Felipe Rodriguez

Nuria Vinolas

Roxana Reyes

Noemi Reguart

Joan Anton Puig-Butille

Affiliations

Soon will be listed here.

Abstract

Background: Analysis of circulating free DNA (cfDNA) by the real-time PCR cobas EGFR Mutation Test v2 (cobas EGFR Test) is a diagnostic approach used in clinical practice for the characterization of advanced non-small cell lung cancer (NSCLC) patients. The test additionally outputs a semiquantitative index (SQI) which reflects the proportion of mutated versus wild-type copies of the gene in cfDNA with potential use as a biomarker. CfDNA concentration and cfDNA fragmentation pattern have also shown potential utility as biomarkers for cancer patients. We evaluated the implementation of testing and cfDNA related parameters in NSCLC patients in routine clinical setting as biomarkers for disease stage and diagnosis.

Methods: A prospective cohort of 173 locally advanced or metastatic NSCLC TKI-naïve patients analyzed by the cobas EGFR Test were included in the study. Reproducibility of the test was assessed in 56 patients. The concentration of cfDNA and fragment size pattern was measured using fluorometry and microchip electrophoresis respectively.

Results: The test showed high diagnostic accuracy when compared to the gold standard of biopsy tumor tissue testing. The SQI value showed a moderate reproducibility (r=0.70) and did not correlate with cfDNA concentration (r=0.17, P=0.28) or disease stage (stage III patients SQI =9.1±3.1 and stage IV patients SQI =11.5±4.8, P=0.41). We found differences in SQI values according to the type of mutation (Ex19Del mutations, SQI =13.6; p.L858R, SQI =8.88; P=0.001). Stage IV patients had higher concentrations of cfDNA (P<0.0001) and higher fractions of cfDNA 100-250 base pairs (bp) fragments (P=0.01) compared to stage III patients. From the ROC curve analysis, cfDNA concentration showed higher AUC compared to cfDNA 100-250 bp fragments (0.86 . 0.71). We obtained a cut-off value for cfDNA concentration of 20.3 ng/mL with 72.3% sensitivity and 95% specificity for predicting disease stage in TKI-naïve advanced NSCLC patients.

Conclusions: The study indicates that cfDNA analysis in plasma for testing by RT-PCR is an accurate and fast method to initially stratify NSCLC patients in a real-world clinical setting. However, the SQI has limited clinical value. The cfDNA concentration and fragmentation pattern have clear potential clinical utility for tumor staging in NSCLC patients.

Citing Articles

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.

Carrasco R, Ingelmo-Torres M, Gomez A, Trullas R, Roldan F, Ajami T Int J Mol Sci. 2022; 23(19).

PMID: 36233035 PMC: 9570339. DOI: 10.3390/ijms231911732.

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.

Honore N, Galot R, van Marcke C, Limaye N, Machiels J Cancers (Basel). 2021; 13(21).

PMID: 34771526 PMC: 8582541. DOI: 10.3390/cancers13215364.

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions.

Gonzalez de Aledo-Castillo J, Serhir-Sgheiri S, Calbet-Llopart N, Arcocha A, Jares P, Reguart N Diagnostics (Basel). 2021; 11(8).

PMID: 34441254 PMC: 8392299. DOI: 10.3390/diagnostics11081319.

References

Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H . Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018; 16(1):300. PMC: 6218961. DOI: 10.1186/s12967-018-1677-2. View

Alegre E, Fusco J, Restituto P, Salas-Benito D, Rodriguez-Ruiz M, Andueza M . Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumour Biol. 2016; 37(10):13687-13694. DOI: 10.1007/s13277-016-5282-9. View

Arriola E, Paredes-Lario A, Garcia-Gomez R, Diz-Tain P, Constenla M, Garcia-Giron C . Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. 2018; 20(10):1261-1267. PMC: 6153859. DOI: 10.1007/s12094-018-1855-y. View

Bronkhorst A, Ungerer V, Holdenrieder S . The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019; 17:100087. PMC: 6425120. DOI: 10.1016/j.bdq.2019.100087. View

Bronkhorst A, Aucamp J, Pretorius P . Cell-free DNA: Preanalytical variables. Clin Chim Acta. 2015; 450:243-53. DOI: 10.1016/j.cca.2015.08.028. View

Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R . Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015; 113(3):476-83. PMC: 4522634. DOI: 10.1038/bjc.2015.225. View

Zulato E, Attili I, Pavan A, Nardo G, Del Bianco P, Boscolo Bragadin A . Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. Br J Cancer. 2020; 123(1):81-91. PMC: 7341732. DOI: 10.1038/s41416-020-0833-7. View

Kim Y, Shin S, Lee K . A Comparative Study for Detection of Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories. Biomed Res Int. 2018; 2018:7392419. PMC: 5964486. DOI: 10.1155/2018/7392419. View

Camidge D, Pao W, Sequist L . Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11(8):473-81. DOI: 10.1038/nrclinonc.2014.104. View

10.

Normanno N, Denis M, Thress K, Ratcliffe M, Reck M . Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2016; 8(7):12501-12516. PMC: 5355360. DOI: 10.18632/oncotarget.13915. View

11.

Ponti G, Maccaferri M, Manfredini M, Kaleci S, Mandrioli M, Pellacani G . The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients. Clin Chim Acta. 2018; 479:14-19. DOI: 10.1016/j.cca.2018.01.007. View

12.

Keppens C, Palma J, Das P, Scudder S, Wen W, Normanno N . Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn. 2018; 20(4):483-494. DOI: 10.1016/j.jmoldx.2018.03.006. View

13.

Soliman S, Alhanafy A, Habib M, Hagag M, Ibrahem R . Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep. 2018; 15:45-51. PMC: 6031238. DOI: 10.1016/j.bbrep.2018.06.002. View

14.

Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

15.

Zhang Y, Xu Y, Zhong W, Zhao J, Chen M, Zhang L . Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget. 2017; 8(4):5861-5873. PMC: 5351596. DOI: 10.18632/oncotarget.14390. View

16.

Arko-Boham B, Aryee N, Blay R, Owusu E, Tagoe E, Doris Shackie E . Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers. Cancer Genet. 2019; 235-236:65-71. DOI: 10.1016/j.cancergen.2019.04.062. View

17.

Li Y, Xu H, Su S, Ye J, Chen J, Jin X . Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One. 2017; 12(8):e0183331. PMC: 5568724. DOI: 10.1371/journal.pone.0183331. View

18.

Li B, Janku F, Jung B, Hou C, Madwani K, Alden R . Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019; 30(4):597-603. PMC: 6503621. DOI: 10.1093/annonc/mdz046. View

19.

Provencio M, Torrente M, Calvo V, Perez-Callejo D, Gutierrez L, Franco F . Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. Oncotarget. 2018; 9(1):488-494. PMC: 5787483. DOI: 10.18632/oncotarget.22470. View

20.

Inamura K . Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017; 7:193. PMC: 5581350. DOI: 10.3389/fonc.2017.00193. View